ASC30

Ascletis' Oral GLP-1 ASC30 Cuts HbA1c 1.7% in Phase II Diabetes Trial

Ascletis' Oral GLP-1 ASC30 Cuts HbA1c 1.7% in Phase II Diabetes Trial

HONG KONG – October 29, 2026 -- Ascletis Pharma (HKEX: 1672) reported that its oral small molecule GLP-1 receptor agonist ASC30 cut HbA1c by a placebo-adjusted 1.7% at the 40 mg dose, 1.6% at 60 mg and 1.7% at 80 mg in a U.S. Phase II study in type 2 diabetes. The 13-week trial (NCT07321678) met its primary endpoint and all secondary endpoints, the company said.

ASC30 delivers placebo-adjusted weight loss of up to 4.4% with no plateau

Placebo-adjusted body weight reductions at 13 weeks were 4.4% (40 mg, n=20), 3.8% (60 mg, n=29) and 4.0% (80 mg, n=28). No weight plateau was observed. Baseline average body weight was 93.7 kg. The weight results were statistically significant versus placebo (p = 0.001 to 0.003).

Ascletis Doses First Patient in Phase III Trial of Oral GLP-1 Pill ASC30

Ascletis Doses First Patient in Phase III Trial of Oral GLP-1 Pill ASC30

Hong Kong – September 03, 2026 -- Ascletis Pharma Inc. has dosed the first participant in a global Phase III program for ASC30, an oral small molecule GLP-1 receptor agonist for chronic weight management, the Hong Kong Stock Exchange-listed biotech confirmed.

Trial enrolls 4,600 participants across three continents

The program comprises two pivotal trials, AURORA-1 and AURORA-2, spanning clinical sites in the U.S., Europe, and Canada. AURORA-1 targets participants with obesity or overweight without type 2 diabetes, while AURORA-2 enrolls those with type 2 diabetes; both trials test 20 mg, 40 mg, and 60 mg maintenance doses against placebo over 72 weeks, with the primary endpoint measuring percentage change in body weight from baseline to Week 72.